The American Diabetes Association’s 2017 Standards of Care were published yesterday in Diabetes Care. While the document itself reads 142 pages…Close Concerns wraps up the highlights as articulated below. For additional reading pleasure, the full 142 page Standards of care report from the ADA is available for reading here.
Key points from the condensed report from Close Concerns
Yesterday, the ADA released its official Standards of Care for 2017, published in Diabetes Care. In this report, we review some of the most notable changes that have been made since the Association’s 2016 Standards of Care and discuss potential implications for the field in the year ahead.
Notably, this newly-released version of the document officially recommends Lilly/BI’s Jardiance (empagliflozin) and Novo Nordisk’s Victoza (liraglutide) for patients with type 2 diabetes at high-risk for cardiovascular events – both are major victories for these compounds.
Additional substantial revisions from the 2016 Standards of Care include the addition of basal insulin/GLP-1 agonist products in the algorithm for type 2 diabetes combination therapy (a major win for drugs approved so recently), an updated definition of clinically-meaningful hypoglycemia at blood sugar <54 mg/dl (the work of the International Hypoglycemia Study Group), a greater overall emphasis on psychosocial support for people with diabetes (a major win), and a focus on the high cost of insulin in the US.